» Articles » PMID: 31467637

Competing Endogenous RNA and Coexpression Network Analysis for Identification of Potential Biomarkers and Therapeutics in Association with Metastasis Risk and Progression of Prostate Cancer

Overview
Publisher Wiley
Date 2019 Aug 31
PMID 31467637
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer (PCa) is the most frequently diagnosed malignant neoplasm in men. Despite the high incidence, the underlying pathogenic mechanisms of PCa are still largely unknown, which limits the therapeutic options and leads to poor prognosis. Herein, based on the expression profiles from The Cancer Genome Atlas (TCGA) database, we investigated the interactions between long noncoding RNA (lncRNA) and mRNA by constructing a competing endogenous RNA network. Several competing endogenous RNAs could participate in the tumorigenesis of PCa. Six lncRNA signatures were identified as potential candidates associated with stage progression by the Kolmogorov-Smirnov test. In addition, 32 signatures from the coexpression network had potential diagnostic value for PCa lymphatic metastasis using machine learning algorithms. By targeting the coexpression network, the antifungal compound econazole was screened out for PCa treatment. Econazole could induce growth restraint, arrest the cell cycle, lead to apoptosis, inhibit migration, invasion, and adhesion in PC3 and DU145 cell lines, and inhibit the growth of prostate xenografts in nude mice. This systematic characterization of lncRNAs, microRNAs, and mRNAs in the risk of metastasis and progression of PCa will aid in the identification of candidate prognostic biomarkers and potential therapeutic drugs.

Citing Articles

New insights into the treatment of polycystic ovary syndrome: HKDC1 promotes the growth of ovarian granulocyte cells by regulating mitochondrial function and glycolysis.

Cong P, Shang B, Zhang L, Wu Z, Wang Y, Li J J Mol Histol. 2024; 55(2):187-199.

PMID: 38478190 DOI: 10.1007/s10735-024-10183-8.


Pro-tumorigenic role of lnc-ZNF30-3 as a sponge counteracting miR-145-5p in prostate cancer.

Le Hars M, Castro-Vega L, Rajabi F, Tabatadze D, Romero M, Pinskaya M Biol Direct. 2023; 18(1):38.

PMID: 37434219 PMC: 10334624. DOI: 10.1186/s13062-023-00393-7.


Development and validation of a genomic instability-related lncRNA prognostic model for hepatocellular carcinoma.

Xun Z, Wang Y, Long J, Li Y, Yang X, Sun H Front Genet. 2023; 13:1034979.

PMID: 36712850 PMC: 9877230. DOI: 10.3389/fgene.2022.1034979.


In Silico Analysis of Ion Channels and Their Correlation with Epithelial to Mesenchymal Transition in Breast Cancer.

Parthasarathi K, Mandal S, Singh S, Gundimeda S, Jolly M, Pandey A Cancers (Basel). 2022; 14(6).

PMID: 35326596 PMC: 8946083. DOI: 10.3390/cancers14061444.


A DNA methylation profile of long non-coding RNAs can predict OS in prostate cancer.

Cheng W, Cao J, Xia Y, Lei X, Wu L, Shi L Bioengineered. 2021; 12(1):3252-3262.

PMID: 34238128 PMC: 8806446. DOI: 10.1080/21655979.2021.1945991.


References
1.
Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L . PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 2000; 97(22):12216-21. PMC: 17321. DOI: 10.1073/pnas.97.22.12216. View

2.
Mabjeesh N, Post D, Willard M, Kaur B, Van Meir E, Simons J . Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 2002; 62(9):2478-82. View

3.
Yin Y, Liu Y, Jin Y, Hall E, Barrett J . PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature. 2003; 422(6931):527-31. DOI: 10.1038/nature01519. View

4.
Azuma H, Inamoto T, Sakamoto T, Kiyama S, Ubai T, Shinohara Y . Gamma-aminobutyric acid as a promoting factor of cancer metastasis; induction of matrix metalloproteinase production is potentially its underlying mechanism. Cancer Res. 2003; 63(23):8090-6. View

5.
Huang J, Liu C, Chou C, Liu S, Hsu S, Chang H . Effects of econazole on Ca2+ levels in and the growth of human prostate cancer PC3 cells. Clin Exp Pharmacol Physiol. 2005; 32(9):735-41. DOI: 10.1111/j.1440-1681.2005.04254.x. View